Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL						
OMB Number: 3235-0287						
Estimated average burden						
hours per response	e 0.5					

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

	pe Response	es)													
1. Name and Address of Reporting Person – NEIS JOHN (Last) (First) (Middle) C/O CELLECTAR BIOSCIENCES, INC., 3301 AGRICULTURE DRIVE (Street)			2. Issuer Name and Ticker or Trading Symbol Cellectar Biosciences, Inc. [CLRB]						5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner						
			DIG 2201	3. Date of Earliest Transaction (Month/Day/Year) 10/12/2018							e title below)		er (specify belo	w)	
			4	4. If Amendment, Date Original Filed(Month/Day/Year)						_X_	6. Individual or Joint/Group Filing(Check Applicable Line) X_ Form filed by One Reporting Person Form filed by More than One Reporting Person				
MADISC	ON, WI 537	716									Form filed by	More than One	Reporting Perso	n	
(City) (State) (Zip)				Table I - Non-Derivative Securities Acqui						Acquired	ired, Disposed of, or Beneficially Owned				
1.Title of S (Instr. 3)			Date (Month/Day/Year)	2A. Deemed Execution Da any (Month/Day/		(Instr. 8		(A (B) (Ir	Securities Acq) or Disposed of astr. 3, 4 and 5) (A) or nount (D)	of (D) Ow Tra	. Amount of Securitie Owned Following Reportansaction(s) Instr. 3 and 4)		ed	Ownership Form:	Beneficial Ownership
	•	•	th class of securities				·	Persons contain	who respored in this for	m are no	t required	l to respoi	nd unless t		474 (9-02)
								ired, Dispo	sed of, or Bene	eficially O					
1. Title of Derivative Security (Instr. 3)	Conversion	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if	4. Transac Code	tion	5. Numb of Derivati Securitie Acquire (A) or Dispose (D) (Instr. 3.	ve es d	ired, Dispo	sed of, or Bend evertible secure ercisable and Date	eficially O	wned ad of	8. Price of	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	Ownersh Form of Derivativ Security: Direct (I or Indire	Beneficia Ownersh (Instr. 4)
Derivative Security	Conversion or Exercise Price of Derivative	Date	3A. Deemed Execution Date, if any	4. Transac Code	tion	5. Numb of Derivati Securitie Acquired (A) or Disposed (D)	ve es d	ired, Disponontions, con 6. Date Exercises Expiration	sed of, or Benevertible secur recisable and Date y/Year)	ficially O ities) 7. Title an Amount of Underlyin Securities	wned ad of	8. Price of Derivative Security	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction	Ownersh Form of Derivativ Security: Direct (I or Indire (s) (I)	of Indirect Beneficia Ownersh (Instr. 4)

Daniel Adding	Relationships					
Reporting Owner Name / Address	Director	10% Owner	Officer	Other		
NEIS JOHN C/O CELLECTAR BIOSCIENCES, INC. 3301 AGRICULTURE DRIVE MADISON, WI 53716	X					

Signatures

/s/ Christina Blakley, attorney-in-fact for John Neis	10/15/2018
**Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- This option grant was divided into a definitive grant of 6,150 shares, which vest in equal monthly installments over a seven month period from the grant date, and a contingent grant of 6,850 shares, which are subject to the following conditions: (i) approval by Cellectar's stockholders of an increase in shares available under the Amended and Restated 2015 Stock Incentive Plan at the Corporation's 2019 annual meeting of stockholders or other special meeting of stockholders called for such purpose; and (ii) to the extent stockholder approval is received, the contingent grant shall vest immediately upon such stockholder approval.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.